March 12, 2019
Takeda Pharmaceutical’s ulcerative colitis (UC) treatment Entyvio (vedolizumab) demonstrated statistical superiority to the TNF-α monoclonal antibody Humira (adalimumab) in achieving clinical remission at week 52 in a PIIIb head-to-head study, the company said. The PIIIb trial, called the VARSITY study,...read more